Supplemental Material - Real-world use and outcomes of belimumab in childhood-onset lupus: A single-center retrospective study | ORKG Ask

We use cookies to provide a better user experience.

Data Protection

Related items

Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort

January 2021

Background: Belimumab was recently approved for treatment of lupus glomerulonephritis (LN). Aim: To ...

A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis

Rovin, B.H.
Furie, R.
Teng, Y.K.O.
Contreras, G.
Malvar, A.
Yu, X.Q.
Ji, B.
Green, Y.
Gonzalez-Rivera, T.
Bass, D.
Gilbride, J.
Tang, C.H.
Roth, D.A.

February 2022

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN),...

Supplemental material for A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus

A Doria (5316149)
D Bass (5316137)
A Schwarting (5316131)
A Hammer (5316158)
D Gordon (5316143)
M Scheinberg (5316161)
N L Fox (5316152)
J Groark (5316146)
W Stohl (5316134)
C Kleoudis (5316140)
D Roth (5316155)

May 2018

<p>Supplemental material for A 6-month open-label extension study of the safety and efficacy of subc...

Supplemental Material - Dilemma of belimumab therapy (dis)continuation during pregnancy: Results of a retrospective study in eudravigilance

Nafise Ghalandari (14202282)
Hubertina JMJ Crijns (14202285)
Radboud JEM Dolhain (14202288)
Johanna MW Hazes (14202291)
Eugene P van Puijenbroek (14202294)

November 2022

Supplemental Material for Dilemma of belimumab therapy (dis)continuation during pregnancy: Results o...

Use of belimumab in real-world in Spain: a scoping review about characteristics of SLE patients.

Escalera, Carlos Rodríguez
Guisado, Ángela María Zurita
Mateo, Francisco Javier
Bahamontes-Rosa, Noemí
Villanueva, María Jesús García

July 2022

Belimumab was the first biological drug approved for Systemic Lupus Erythematosus (SLE). There is no...

First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study

Andreas Schwarting (629)
Johann O. Schroeder (5081411)
Tobias Alexander (503838)
Marc Schmalzing (5081426)
Christoph Fiehn (5081417)
Christof Specker (5081420)
Alessandra Perna (5081408)
Constanze Cholmakow-Bodechtel (3995375)
Volker B. Koscielny (5081414)
Heike Carnarius (5081423)

April 2018

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

Brunner, H
Abud-Mendoza, C
Viola, D
Penades, I
Levy, D
Anton, J
Calderon, J
Chasnyk, V
Ferrandiz, M
Keltsev, V
Paz Gastanaga, M
Shishov, M
Boteanu, A
Henrickson, M
Bass, D
Clark, K
Hammer, A
Ji, B
Nino, A
Roth, D
Struemper, H
Wang, M
Martini, A
Lovell, D
Ruperto, N

October 2020

Objectives: This ongoing Phase-2, randomised, placebo-controlled, double-blind study evaluated the ...

Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort

January 2021

Background: Belimumab was recently approved for treatment of lupus glomerulonephritis (LN). Aim: To ...

A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis

Rovin, B.H.
Furie, R.
Teng, Y.K.O.
Contreras, G.
Malvar, A.
Yu, X.Q.
Ji, B.
Green, Y.
Gonzalez-Rivera, T.
Bass, D.
Gilbride, J.
Tang, C.H.
Roth, D.A.

February 2022

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN),...

Supplemental material for A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus

A Doria (5316149)
D Bass (5316137)
A Schwarting (5316131)
A Hammer (5316158)
D Gordon (5316143)
M Scheinberg (5316161)
N L Fox (5316152)
J Groark (5316146)
W Stohl (5316134)
C Kleoudis (5316140)
D Roth (5316155)

May 2018

<p>Supplemental material for A 6-month open-label extension study of the safety and efficacy of subc...

Supplemental Material - Dilemma of belimumab therapy (dis)continuation during pregnancy: Results of a retrospective study in eudravigilance

Nafise Ghalandari (14202282)
Hubertina JMJ Crijns (14202285)
Radboud JEM Dolhain (14202288)
Johanna MW Hazes (14202291)
Eugene P van Puijenbroek (14202294)

November 2022

Supplemental Material for Dilemma of belimumab therapy (dis)continuation during pregnancy: Results o...

First Real-World Insights into Belimumab Use and Outcomes in Routine Clinical Care of Systemic Lupus Erythematosus in Germany: Results from the OBSErve Germany Study

Andreas Schwarting (629)
Johann O. Schroeder (5081411)
Tobias Alexander (503838)
Marc Schmalzing (5081426)
Christoph Fiehn (5081417)
Christof Specker (5081420)
Alessandra Perna (5081408)
Constanze Cholmakow-Bodechtel (3995375)
Volker B. Koscielny (5081414)
Heike Carnarius (5081423)

April 2018

<p><b>Article full text</b></p> <p><br></p> <p>The full text of this article can be found here<b>....

Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial

Brunner, H
Abud-Mendoza, C
Viola, D
Penades, I
Levy, D
Anton, J
Calderon, J
Chasnyk, V
Ferrandiz, M
Keltsev, V
Paz Gastanaga, M
Shishov, M
Boteanu, A
Henrickson, M
Bass, D
Clark, K
Hammer, A
Ji, B
Nino, A
Roth, D
Struemper, H
Wang, M
Martini, A
Lovell, D
Ruperto, N

October 2020

Objectives: This ongoing Phase-2, randomised, placebo-controlled, double-blind study evaluated the ...

Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort

January 2021

Background: Belimumab was recently approved for treatment of lupus glomerulonephritis (LN). Aim: To ...

A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis

Rovin, B.H.
Furie, R.
Teng, Y.K.O.
Contreras, G.
Malvar, A.
Yu, X.Q.
Ji, B.
Green, Y.
Gonzalez-Rivera, T.
Bass, D.
Gilbride, J.
Tang, C.H.
Roth, D.A.

February 2022

We performed a post hoc analysis of the Belimumab International Study in Lupus Nephritis (BLISS-LN),...